Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.

Yuta YokoyaAtaru IgarashiAkihito UdaHisato DeguchiToshihisa TakeuchiKazuhide Higuchi

Published in: Journal of gastroenterology (2019)

Vonoprazan-first strategy increased QALYs and appeared to be cost-effective for GERD patients compared with the esomeprazole- or rabeprazole-first strategies.

Keyphrases

gastroesophageal reflux disease
helicobacter pylori
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
endoscopic submucosal dissection
patient reported